aggress cut outlook other
taken think mix conservat
juxtapos cognit disson compani
say cant predict futur reiter guidanc
pull franchis convers ultomiri
acceler sever diseas benefit improv care
pivot away cell therapi given infect
push franchis insur switch
medicaid complex multi-disciplinari sale therapi
initi delay blood tests/vaccin
ultomiri dose higher
indic work price succe
updat model chang pt remain top
onpattro sale slightli ahead consensu ex-u
strength givlaari encourag earli start
onpattro guidanc lower covid
impact expect recoveri move home infus
top-line data aln-agt hypertens
agt knockdown reduct hour sbp
aln-cov acceler ind file around ye
royalti pipelin revenu pt remain
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
voluntari execut pay cut mostli off-set
dilut stock grant trade number
folk express disappoint updat
cinvanti better expect gener
arbitrag weigh lift earli along
sustol drive meaning inflect
progress hospit eager restart surgeri
plan catch lost
acceler procedur discharg enabl
updat model pt remain top pick
latter part
move higher dose cohort danon dose patient
start sooner data asgct updat
strong benefit nash resolut seen qd arm vs
pbo high end rang landscap
fibrosi mix stat sig though indic trend call
differ vs pbo well improv slow progress
gi toler remain consider possibl weekli dose
titrat may lower low rate discontinu nausea isnt bad thing
weight loss
expect high head read-out lack fibrosi benefit gi
toler leav room addit nash/liv specif therapi
major surpris result
ultra-deep pipelin lot shot goal continu advanc
model revis reflect commerci headwind pt remain
expect set major catalyst data readout posit nda
keveyi revenu line expect highest number patient ever
drug april improv patient retent
conserv lower full year keveyi guidanc despit strong due
impact face-to-fac interact sign outsid pandem
potenti continu keveyi growth
cash hand maintain enough fund
pt deriv dcf discount rate
risk op rate includ slower expect onpattro ramp ttr
market opportun well key pipelin failur
deriv valuat base dcf use discount
rate appli commerci stage biotech compani termin growth
rate reflect optimist outlook durabl compani
franchis includ million product revenu reflect potenti
busi develop
risk price target includ intensifi competit threat formid
biopharma compani along potenti amplifi price pressur failur
deriv pt use dcf discount rate
face develop regulatori commercial/competit risk gene therapi
car-t portfolio
price includ dilut convert note option
deriv dcf base discount rate termin
growth rate discount rate lower normal smid cap coverag univers
reflect derisk natur termin growth rate account new
product launch time signific spend built
risk includ failur secur approv commerci execut failur
cinv franchis risk potenti legisl chang medicar part
reimburs sustol cinvanti face competit risk respect
deriv pt dcf model use discount rate
termin growth reflect solid pipelin challeng revenu base grow
includ meaning contribut spinraza sale reach
declin gene therapi risdiplam imping includ modest contribut
ttr fap program believ remain domin
indic includ contribut huntington sale reach
includ meaning contribut program lump catch basket
deliv anoth revenu plenti potenti driver
includ factor xi antisens program bayer develop prevent thrombosi
esrd hemodialysi popul despit project partner gener mani
billion revenu captur
relev risk
inflamm
thrombocytopenia develop pursu sub-optimal target deliveri approach
regulatori especi light certain drug side effect profil commerci
particularli compani propens outlicens program captur full
issu
price deriv dcf includ termin
valu base discount rate termin growth rate reflect grow product
begin life cycl long live
emerg gene therapi compani may go multipl iter
optim approach like could face competit improv allogen
transplant addit gene therapi field need defin busi model
dcf revenu multipl compani comp hybrid approach peak sale
commerci launch failur physician may resist switch patient recorlev payer
pushback enantiom super-cheap off-label ketoconazol may payer
pushback recorlev premium price patient may avoid higher
articl articl
time dissemin may pm et
analyst josh schimmer angela ni maneka mirchandaney primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani
issuer part research analyst compens directli relat specif recommend view
research report
